PM = Programme Management (resource needed) BAU = Business As Usual (no additional resources)

Strategic Activity BSC1 NHSBT will ensure the collection of sufficient red cells and platelets to meet current and future demand by modernising blood collection activities.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
1a) Redress the decline in blood collection focusing on targeted donor marketing and communications activities:						
o Implement short-term initiatives focused on retention and frequency - cumulative reduction in potential "do nothing" shortfall	CRo	PM	11K	14K	12K	13K
Improved planning of marketing and communication activities to be more effective in attracting and retaining donors						
<ul> <li>Retained / maintained frequency of 3 times donors through a specific marketing campaign. (Increase in the number of donors donating three times in the year)</li> </ul>						
• Conversion of new donors into second donation by differentiating the service and communications. (Number of new donors who donate for a second time within six months of first donation)						
<ul> <li>Sending SMS or e-mail appointment reminders. (Proportion of donors from target group for who we hold the relevant information)</li> </ul>						
Tracing donors lost due to change of address (Proportion off "lost donors" that we have tried to trace)						
<ul> <li>Achieve whole blood collection target 1.890m in 2008/09</li> </ul>	CRo	BAU	476k	482k	461k	471k
<ul> <li>Medium to long-term initiatives focused on defined sections of the donor population and areas where collection rates are currently poor (London and North West) – plan segments and target areas</li> </ul>	CRo	РМ	Plai	nning and evalu	ation	Feasibility assessed
1b) Increase donor satisfaction through improved session convenience, increasing the percentage of blood donors very / totally satisfied from 63% to 65%						
o Plan Decoupling panels	CRo	РМ				Plan & specification written
<ul> <li>Plan revised opening times and more accessible locations</li> </ul>	CRo	РМ				Plan & approach signed off
<ul> <li>Pilot collection centre sited with retail partner – Boots in Poole</li> </ul>	CRo	РМ			Site in Poole operational	Ramp up Collections
o Double dose red cells	CRo	PM			quirement & ibility	

Strategic Activity BSC1 NHSBT will ensure the collection of sufficient red cells and platelets to meet current and future demand by modernising blood collection activities.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4	
--	--------------	-------------	-----------	-----------	-----------	-----------	--

<ul> <li>1c) Increase operational productivity (&amp; improve donor experience) through the implementation of a donation operational improvement programme – redesign and pilot new processes</li> <li>The quarter 4 targets will be achieved In the areas where roll out has been completed</li> </ul>	CRo	PM	Pilot/ evaluation	Commence Roll-out	Continue Roll-out	Continue Roll-out Reducing total queuing time by 20% and end-to- end donation time by 15% Collect to target
1d) Develop plans to import red cells as an important aspect of NHSBT contingency planning – feasibility study	PAG	BAU	Report to EMT			

Strategic Activity BSC2 NHSBT will avoid further significant increases in red cell prices by reducing costs and improving efficiency in line with expected falls in blood demand.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
The 2008/09 cost reduction programme (£10.2m) is reflected in baseline budgets. Delivery will be monitored via the cumulative income and expenditure position (including Group Services)			I&E to plan	I&E to plan	I&E to plan	I&E to plan
2a) Reductions in supply chain costs related to the continued decline in blood component demand - £4.6m	CRo	BAU		£		
2b) Reductions in cost and efficiencies from increasing capacity utilisation through consolidation and productivity improvements within processing and testing and by implementing best practice (linked to 3a) - £0.3m	CRo	BAU				
2c) Implementation of an operational improvement programme to deliver greater productivity in blood collection (linked to 1c) - £1.4m	CRo	BAU				
2d) Procurement savings - £2.5m	RB	BAU				
2e) Release of non-recurring safety funding in prices - £1.4m	CRo	BAU				

Strategic Activity BSC3 NHSBT will ensure that the organisation has the appropriate level of capacity and capability to process blood to the standards required by modernising its production and testing infrastructure.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4	
3a) Increasing capacity utilisation through consolidation, productivity improvements and by implementing best practice (5,300 units of red cell (equivalent) per WTE productivity within P&T).							
<ul> <li>Complete the consolidation in the South West on-time and to budget</li> </ul>							
Complete the new build at Filton	DD	PM	By Mid-June				
Filton business readiness and occupation	CRo	РМ	Planning	SCI, BITS and office moves into Filton	100% of Southmead and Aztec West		
South West regional operations	CRo	РМ	New Leadership Team in place			New SW service model in place	
Complete the relocation of Donation Testing into Filton	CRo	РМ	Planning and staff consultation	Planning and staff consultation MHRA licensing	Routine Testing move into Filton	NAT move into Filton	
Complete reconfiguration of Issue (Hospital Services) facilities in the South West	CRo	РМ	Planning and staff consultation	Planning and staff consultation MHRA licensing	Move Issue from Southmead to Filton	Implement action of new model	
Complete consolidation of Processing (manufacturing) into Filton	CRo	PM	Planning and staff consultation	Planning and staff consultation MHRA licensing	Move manufacturi ng from Southmead into Filton	Consolidatio n of manufacturi ng into Filton	
Complete logistics and supply chain reconfiguration in the South West	DD	РМ	Planning	Planning	Planning	Implement new service model	
<ul> <li>Plan consolidation in the South East and North in advance of consultation beginning in 2009/10</li> </ul>	CRo	РМ	Planning				
<ul> <li>Develop logistics infrastructures in the SE and North to support planned consolidations in the regions</li> </ul>	DD	BAU	Planning				
<ul> <li>Operational improvement programme linked to consolidation</li> </ul>	CRo	РМ		Plan	ining		

Strategic Activity BSC3 NHSBT will ensure that the organisation has the appropriate level of capacity and capability to process blood to the standards required by modernising its production and testing infrastructure.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4	
o Replenishment model – improvements to the distribution of blood components to hospitals and NBS stock holding units	CRo	PM		Planning		Pilot	
<ul> <li>Estates optimisation - improvements in space utilisation – decommission Bristol Aztec West</li> </ul>	DD	BAU			By December		
3b) Initiatives which contribute to delivering 'compliance' targets (zero 'critical non-compliances and 0% of external non-compliances with overdue actions).							
<ul> <li>Reinforce a compliance culture through increased self-inspection resource to identify and correct problems in advance, ensuring all major non-compliances are managed effectively and within defined timescales - Recruit and train staff and increase internal inspection</li> </ul>	CRo	BAU	Ongoing				
<ul> <li>Plan for non-compliance - to reduce the percentage of external non-compliance with overdue actions from c14% to 0% in line with the strategic plan targets</li> </ul>	CRo	BAU	Ongoing				
3c) Implementation of improved service to hospitals (53% of hospitals very / totally satisfied)							
<ul> <li>Develop process maps for all NBS / hospital service interactions and identify improvements which add value to the customer</li> <li>Implement quick win changes</li> <li>Work with IT and supply chain managers to plan longer term initiatives for implementation 09/10</li> </ul>	CRo	РМ	Process maps complete by end June08	Develop & initiate promotional campaign to introduce foetal genotyping	Outline plan for longer term initiatives By Nov for Mid- Yr 2008/09	Develop & initiate promotional campaign NBS sci & tech training	
<ul> <li>Improve hospital customer satisfaction scores with respect to NBS decision making and strength of partnership through a programme of pro-active interactions with key customers</li> <li>Initiate face to face customer satisfaction survey completion with key accounts</li> </ul>	CRo	BAU	Hospital key account visits complete	Initiate "customer value" visits with strategy teams	Define service standards for Specialist Services	3 percentage points increase in top 2 boxes	
<ul> <li>Implement initiatives to improve performance related to the level of component ordering/despatch errors demonstrated through a reduction in complaints and an improvement in the top box score for accuracy of delivered orders (baseline 25% top box satisfaction)</li> <li>Undertake hospital audit of ordering substitutions</li> </ul>	CRo	BAU	Complete audit of order substitutions	Implement service excellence with Issues & Logistics staff in SW	Implement service excellence with Issue & Logistics staff in L&SE & North		

	egic Activity BSC3 NHSBT will ensure that the organisation has the appropriate level of capacity and capability to process to the standards required by modernising its production and testing infrastructure.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
0 0 0	Increase hospital satisfaction with service from non NBS drivers Initiate pilot of platelet issue via NBS drivers Hospital Liaison to work with logistics to define customer centric performance measures in courier contract	CRo	BAU	Transport survey feedback to hospitals	Define customer values criteria for courier contract	Implement pilot of platelet issue	
0	Provide hospitals with comparative data sets on red cells, platelets and frozen components to assist hospitals in meeting CMO BBT3 and compliance requirements	CRo	BAU	Develop Business Objects queries	Issue Red cell datasets to RTCs	Issue platelet & frozen component datasets	Refine and review dataset format

Strategic Activity BSC4 NHSBT will reduce the residual risk of transfusion through continued implementation of agreed blood safety initiatives.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
4a) Ongoing implementation of blood safety initiatives (reduction in red cell issues of 1.765m / 3%)						
• Continued implementation of expanded platelet production by component donation increasing production to 80% by year-end	CRo	BAU	Plans developed and potential assessed	Roll out	Roll out	80%
<ul> <li>NHSBT will continue to lead the CMO's BBT initiatives introducing new steps to:</li> </ul>						
Reduce inappropriate use of ORhD negative red cells through audit and provision of comparative data	CRo	BAU	Develop audit tool, consider how to facilitate inter-hospital transfers	Audit sent to hospitals for completion	Audit report issued to hospitals	Group ORhD neg constitutes <11 % of total red cell issues
<ul> <li>Reduce inappropriate use of FFP and platelets through audit and provision of comparative data, strengthening the evidence base through systematic literature reviews and clinical trials, and contribution to guidelines in areas of critical care, cardiac surgery and haematology</li> </ul>	LW	BAU	Audit sent to hospitals for completion	Audit report issued to hospitals	Review comparative data with RTCs	<340,000 frozen components issued <214,000 platelets issued
<ul> <li>Reduction in errors resulting in ABO incompatible red cell transfusions reported to SHOT by continuing education, training and audit; exploring new approaches to error reduction in conjunction with NPSA, NBTC and SHOT.</li> </ul>	LW	BAU	2.5	2.5	2.5	2.5
• Extend the use of imported virus inactivated plasma from low risk BSE countries for the preparation of cryoprecipitate for children	CRo	BAU	Stock building Import 2.5k units	Make product available Import 2.5k units	Import 2.5k units	Import 2.5k units
<ul> <li>Develop new overarching measure for monitoring of blood safety (including donor safety)</li> </ul>	LW	BAU	Ongoing	Complete by mid-year		

Strategic Activity BSC4 NHSBT will reduce the residual risk of transfusion through continued implementation of agreed blood safety initiatives.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4	
---	--------------	-------------	-----------	-----------	-----------	-----------	--

4b) Ongoing evaluation of further potential blood safety plans						
<ul> <li>Implications of red cell prion filtration – NHSBT will continue to participate in the UK Blood Services Prion Reduction Working Group</li> </ul>	LW	BAU	Option appraisal to SaBTO by 30 April	Commence filter arm of Study A	Product for exchange transfusion	Plan for Study B
• Implications of a licensed test for vCJD - NHSBT will continue to participate in the UK Blood Services Prion Assay Working Group	LW	BAU	Option appraisal to SaBTO by 30 April	Ongoing evaluations	Ongoing evaluations	Ongoing evaluations
<ul> <li>Further testing and processing initiatives to reduce TRALI: screening of potential female platelet donors, manufacture of cryoprecipitate from male donors</li> </ul>	CRo	BAU	Ongoing	Ongoing	Ongoing	Ongoing
<ul> <li>Evaluate whether bacterial screening or pathogen inactivation of platelets should be considered for phased implementation</li> </ul>	LW/ PAG	PM to BAU	Ongoing clinical study	Complete clinical study	Option appraisal to SaBTO	Plan for implementati on as required

### Appendix 1 NHSBT Work-Plan 2008/09 Strategic Objective b) Specialist Services

Strategic Activity SS1 Implement appropriate funding and pricing strategies to eliminate inappropriate cross-subsidies.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
<ul> <li>Price and funding targets have been reflected in each service budget for 2008/09 – delivery will be monitored via the cumulative income and expenditure position for specialist services</li> </ul>	PAG	BAU	I&E to plan	I&E to plan	I&E to plan	I&E to plan

Strategic Activity SS2 Expand in areas of anticipated high growth without increasing capacity unnecessarily.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
o Increase H&I referrals to support the increase in solid organ and stem cell transplantation	PAG	BAU	2%	3%	4%	5%
<ul> <li>Increase Clinical Stem Cell procedures through increased business development</li> </ul>	PAG	BAU	2%	3%	4%	5%
<ul> <li>Increase the number of Cord Blood units held in stock</li> </ul>	PAG	РМ	10,600	11,200	11.850	12,500
<ul> <li>Increase the proportion of Black and Minority Ethnic (BME) Cord Blood units held in stock.</li> </ul>	PAG	РМ	40%	40.3%	40.7%	41%
<ul> <li>Increase Tissue sales through increased marketing and product development</li> </ul>	PAG	BAU	2%	3%	4%	5%
<ul> <li>Introduce foetal genotyping from maternal blood</li> </ul>	PAG	BAU	Continue validation at Southmead	Procure Equipment	Plan for implementati on	Complete plan

Strategic Activity SS4 Ensure that service quality levels are maintained or improved during the ongoing change programme.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
<ul> <li>Percentage of hospitals satisfied with overall service (RCI - top two boxes)</li> <li>Maintenance of excellent communications and service during period of change</li> </ul>	PAG	BAU	57%	57%	57%	57%
<ul> <li>Achieve RCI turnaround targets</li> </ul>	PAG	BAU	95%	95%	95%	95%
<ul> <li>Achieve H&amp;I turnaround targets</li> </ul>	PAG	BAU	80%	80%	80%	80%
<ul> <li>Achieve SCI turnaround targets</li> </ul>	PAG	BAU	90%	90%	90%	90%

### Appendix 1 NHSBT Work-Plan 2008/09 Strategic Objective b) Specialist Services

Strategic Activity SS3 Reduce costs and improve efficiency from realising synergies, consolidation and divesting from activities in a managed way ensuring continued patient safety.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
Consolidate RCI reference services						
<ul> <li>Complete the move of Southampton to Filton</li> </ul>	PAG	PM	Plan	Complete		
<ul> <li>Plan the move of Manchester to Liverpool</li> </ul>	PAG	PM	Plan	Plan	Plan	Plan
<ul> <li>Plan alternatives for Cambridge (Addenbrookes or Colindale)</li> </ul>	PAG	PM	Plan	Plan	Plan	Plan
Consolidate Reagent services						
<ul> <li>Complete the move of Birmingham to Liverpool</li> </ul>	PAG	PM	Plan	Complete		
<ul> <li>Complete the move of Cambridge to Liverpool</li> </ul>	PAG	PM	Plan	Complete		
Consult with hospitals affected by divestment of routine ante natal services, and plan alternatives for each. Cessation by 2010/11.	PAG	РМ	Appoint Project Team	Draft Business Case	Early consultation	Consultatior complete
Consolidate BBMR, H&I, SCI and CBB services in one location.						
<ul> <li>Transfer Cord Blood Bank from Edgware (CBB) to Filton</li> </ul>	PAG	РМ	Plan	Plan	Draft Business Case	Consultation
<ul> <li>Donor-facing H&amp;I activities from Colindale to Filton</li> </ul>	PAG	PM	Plan	Plan	Draft Business Case	Consultatio
Alignment of H&I and RCI services into a single diagnostics function	PAG	PM/ BAU			Draft Business Case	Early Implementa on
SCI efficiencies and growth						
<ul> <li>Transfer SCI Cambridge to Addenbrookes Hospital</li> </ul>	PAG	BAU	Complete			
o Embed Manchester SCI in Liverpool	PAG	PM	Plan	Plan	Plan	Plan
H&I efficiencies and growth	PAG	BAU				Review logistics for PGI
RCI efficiencies and growth	PAG	BAU	Develop workforce plan	Filton pilot extended working day	-	

### Appendix 1 NHSBT Work-Plan 2008/09 Strategic Objective c) Organ Donation

Strategic Activity OD1 Remove the obstacles to organ donation and effectively performance manage the identification and referral of potential donors.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
<ul> <li>Implementation of clinical "Donor Champions" and an Organ Donation Committee within 51 (c19%) donating hospitals (ODTF recommendation 4)</li> </ul>	тм	РМ	JDs and recruitment process			51 / 19%
o Implement effective performance management with donating hospitals within all donating hospitals (ODTF recommendation 6)	ТМ	РМ	Indicators for HCC standards	Indicators for HCC standards		
<ul> <li>Implement financial reimbursement to all NHS Trusts for the additional costs incurred when facilitating a potential or actual donor (ODTF Recommendation 8)</li> </ul>	тм	PM	Preparation	Q1 in July	Q2 in October	Q3 in January
Strategic Activity OD2 Maximise the conversion of potential donors into actual donors by developing and implementing a robust, sustainable donor co-ordination service (ODTF 9).						
<ul> <li>Implementation of a centrally employed Donor Transplant Co-ordinator network in four teams</li> </ul>	ТМ	РМ	Commence recruitment of new staff			4 teams (not fully operational)
<ul> <li>Improve, and streamline, the process of donor registration through the introduction of an electronic (web-based) system</li> </ul>	тм	PM	Architecture developed	Application development underway	Application development complete	Pilot EOS system deployed
<ul> <li>Maintain and increase the current level of investment in Living Donor schemes, through funding the deployment of 4 additional Live Donor co-ordinators</li> </ul>	CRu	BAU	SLAs in place April	Funding new living donor schemes		30 live donor co- ordinators
Strategic Activity OD3 Develop and implement a flexible, robust and sustainable organ retrieval service that delivers viable organs to transplant units (ODTF 10).						
<ul> <li>Implement nationally commissioned Organ Retrieval Teams (ODTF 10) - develop a framework within which the commissioning of Organ Retrieval Teams can be implemented in time for the 2009/10 financial year</li> </ul>	тм	PM	Develop specification and model	Commiss'ng agreements for 2009/10	Deployed November	NHSBT commiss'ng capability
Strategic Activity OD4 Develop and implement a robust, sustainable cornea donation service.						
<ul> <li>Review eye retrieval units - performance manage each against a target of retrieving 70% of all donated corneas by 2011/12, whilst achieving an annual quality indicator of 70% retrieved corneas suitable for transplantation</li> </ul>	CRu	BAU				3 units
Strategic Activity OD5 Implement methods to publicly recognise the act of donation and actively promote donation to the public.						
<ul> <li>Plan and develop a national public awareness campaign (implement in 2009/10).</li> </ul>	HJ	BAU	4	Plan and	l develop	
<ul> <li>Promoting organ donation and the "gift of life" to the general public, and specifically to the BME population, via targeted marketing campaigns (ODTF recommendation 13). This will include the commissioning of research through DH Research and Development funding</li> </ul>	HJ	BAU		Develop marketing campaigns	Implement campaigns	Implement campaigns
<ul> <li>Promoting public recognition of individual organ donors through national memorials, local initiatives and personal follow up to all donor families (ODTF recommendation 12)</li> </ul>	ТМ	РМ		Develop specification for commissioni ng research	Commission research	

### Appendix 1 NHSBT Work-Plan 2008/09 Strategic Objective d) Fractionated Products

Strategic Activity FP1 Increase capacity and throughput.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
<ul> <li>Increase annual fractionation capacity by 4%</li> </ul>	JM	BAU				483k L
o Average batches per week	JM	BAU				1.75
<ul> <li>Capital Investment – cumulative expenditure</li> </ul>	JM	BAU	£1.1m	£2.7m	£4.3m	£6.5m
o Budgeted WTE	JM	BAU	432	432	432	432
Strategic Activity FP2 Develop new products and expand into key markets						
o Launch new products	JM	BAU				
Optivate sales in Europe			MHRA advice – clinical data refresh	MHRA expert report	January	Mutual recognition filing
Replenine sales in Europe			MHRA advice – clinical data refresh	MHRA expert report	January	Mutual recognition filing
<ul> <li>Contract fractionation (CFr) - Licensing out BPL IP (LO)</li> </ul>	JM	BAU				
Gammacan – contract signed (trial 2 – plasma dependant)			April	Clinical trial batches - 1	Clinical trial batch -2	
Anti-D – contract signed			Preliminary contract discussion	ТВА	ТВА	ТВА
Strategic Activity FP3 Increase home and export sales revenues						
<ul> <li>Deliver home sales plan – year on year increase of £8.5m</li> </ul>	JM	BAU	£17.1m	£34.3m	£51.4m	£68.5m
<ul> <li>Deliver export sales plan – year on year increase of £2.1m</li> </ul>	JM	BAU	£5.9m	£11.8m	£17.7m	£23.7m
Strategic Activity FP4 Consider options for commercial partnership		<u>.</u>				
<ul> <li>Respond to the outcome of Ministerial review of the OBC on ownership options</li> </ul>	LH &JM	BAU	твс	твс	твс	TBC

Strategic Activity EA1 Ensure NHSBT corporate structures enable effective and efficient delivery of its strategy through the provision of appropriate organisational structures and systems	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
<ul> <li>NHSBT: Implementation of a revised organisation structure that integrates formation of an Organ Donor Organisation and demonstrates further synergies across its total supply chain</li> </ul>	LH	BAU	Outline structure agreed and four of the new posts advertised and selection completed	Top Team in place, Operational Divisions changes agreed. Board Developmen t Plan in place	Organisation al Developmen t Plan agreed	
<ul> <li>NHSBT: Review of Group Services - planning delivery of cost reductions and efficiencies in support service functions in line with external benchmarks</li> </ul>	LH	BAU				Begin January
<ul> <li>Complete the realignment of support team sub-structures to enable successful delivery of strategic plans</li> </ul>						
<ul> <li>Clinical: Develop an R&amp;D strategy that recognises the need for succession planning, the opportunities presented by the creation of the National Institute for Healthcare Research, and includes proposals for structuring of development.</li> </ul>	LW	BAU	Gather information on development activities	Formulate plans for Research	Present plan to NHSBT Board	Commence implementati on
Clinical: Review the current structure of the Clinical Directorate in the light of NHSBT organisational restructure	LW	BAU	Option appraisal and development of job descriptions	Appoint to new structure	Further appointment s	New structure in place
<ul> <li>Implement a reorganisation of the HR Function to provide a more effective and responsive general HR and recruitment service.</li> </ul>	DE	BAU	Ongoing	Restructure complete		
• Finance: Continue the restructure / development of Finance to improve support to the development & delivery of strategy.	RB	BAU				By March
IT: Implement the IT organisational change to deliver the structure outlined in the IT Strategy	AMcD	BAU			IT organisation blueprint agreed.	Security Mgmt, Business Systems Solutions Mgmt and Relationship Mgmt structures in place.

Strategic Activity EA1 Ensure NHSBT corporate structures enable effective and efficient delivery of its strategy through the provision of appropriate organisational structures and systems	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
<ul> <li>Communications &amp; Public Affairs:</li> <li>Restructure of the CPA Directorate (the subsequent activities are dependent on this)</li> <li>Development and introduction of a single internal communications function across NHSBT</li> <li>Development and introduction of a single professional and responsive press and media function across NHSBT – with one integrated on-call team</li> <li>Recruitment of staff with relevant experience to build a Public Affairs function</li> </ul>	HJ	BAU			Single NHSBT magazine Begin the process of developing a single NHSBT Intranet	
<ul> <li>Review and develop NHSBT's Governance systems</li> </ul>						
NHSBT: Maintenance and development of an effective emergency preparedness infrastructure and framework						
Renewed SLA DH Antidote service in place	CRo	BAU	Signed SLA in place			
Flu pandemic plans in place and mechanism for regular review.	CRo	BAU	Develop assessment tool in collaboration with DH.	Gap analysis.	Report on Flu Preparednes s	
Review EP management arrangements	CRo	BAU	Report for NBS SMT	Business case(s) if required		
• DSM: Development of an action plan in response to NHSBT's NHSLA and Standards for Better Health self-assessments	ТМ	BAU	Action Plan agreed & Implemen'd	Q2 update report	Q3 update report	Actions complete Q4 report
DSM: Implementation of the findings from the review of risk management systems and processes	ТМ	BAU	Recommend ations and actions agreed	Implementati on	Implementati on	Actions complete
DSM: Development of an integrated NHSBT Sustainable Development Action Plan	TM	BAU	SDAP developed	Agreement & Implementati on of actions	SDAP integrated to NHSBT Planning & Governance Processes by December	
Finance: complete benchmarking analysis with NHS SBS and develop an action plan	RB	BAU				March

Strategic Activity EA1 Ensure NHSBT corporate structures enable effective and efficient delivery of its strategy through the provision of appropriate organisational structures and systems	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
<ul> <li>Clinical: Review Clinical Governance arrangements, including Clinical Audit, with a view to improving the integration of Clinical Governance issues within NHSBT's management arrangements</li> </ul>	LW	BAU	Clinical Audit Workshop, Medicines Mgt, Infection Control	Adverse events, medical records.	Present proposals to the Board	New arrangement s in place
<ul> <li>Review and develop NHSBT's systems in support of key strategic deliverables</li> </ul>						
IT: Complete the consolidation of Pulse onto new hardware and a single database	AMcD	РМ	New hardware fully validated and in place and migration plans agreed with stakeholders	Migration complete		
IT: Continue to renew the components of Pulse, with business support	AMcD	PM		Version 15.3 & 15.4 live	Version 16.1 live	
IT: Replacement telecommunications system procured and deployment underway	AMcD	PM		Award contract	25% complete	50% by year-end
• IT: Implement the new standardised Laboratory Information Management System (Hematos) in line with project milestones	PAG	PM	Ongoing	H&I BBMR HITS live	CBB & BBMR office	SCI live
IT: With Donor Services support, IT Session infrastructure replacement.	AMcD	РМ	Procurement underway. Rollout plans agreed with DS.	Procurement complete. Rollout ongoing.	Rollout meets targets agreed with DS.	Rollout meets targets agreed with DS.
IT: Enterprise print management system procured and deployed in Filton.	AMcD	РМ	Planning complete and procurement begins	Procurement complete and deployment begins	Deployment complete	
IT: NBS Data Warehouse developed and deployment underway.	AMcD	РМ		Begin development and procurement	Complete development and procurement	Deployment commenced
IT: Plan and design the infrastructure for the UKT ODO	AMcD	РМ		Planning and design work for ODO underway	Planning and design complete	Initial implementati on

Strategic Activity EA1 Ensure NHSBT corporate structures enable effective and efficient delivery of its strategy through the provision of appropriate organisational structures and systems	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
IT: Secure corporate data on NHSBT laptops and removable media	AMcD	PM	Procure encryption. Begin to implement	Implementati on continues	Complete implementati on	
<ul> <li>IT: Upgrade core IT infrastructure components - <ol> <li>Active Directory,</li> <li>Data centre SAN,</li> <li>Microsoft Exchange</li> <li>Core Network,</li> <li>Web Services Components.</li> </ol> </li> </ul>	AMcD	РМ	<ol> <li>deployment plan agreed.</li> <li>4 design in progress.</li> <li>5. Design and implementati on plans developed.</li> </ol>	<ol> <li>deployment in progress</li> <li>Detailed requirement s complete</li> <li>design requirement s complete.</li> <li>Frocurement begins</li> </ol>	1. deployment in progress 2. procurement 4. procurement 3. requirement 5. Procurement complete and deployment begins	1. deployment complete 2. Contract award deployment started 4. Contract award deployment started 3. procurement complete 5. deployment complete
Function?: Development of a system for the 35 outstanding transplant-related datasets	CRu / AMcD	BAU	Initial analysis	Requirement Defined		
Finance: Upgrade Oros ABC software to SAS ABM to enable improved performance reporting, drill down access, improved model automation and data integration	RB	РМ	Ongoing	Complete		
Finance: Complete ABC iteration 4 and 5 including UKT.	RB	BAU	Ongoing	Ongoing	October	
Finance: Complete the feasibility study on Intelligent invoice processing	RB	РМ	-			March
Finance: Integration of core systems into billing processes / completing the review of Debtors processes completed	RB	BAU		September		
Finance: Progress ESR Benefits Realisation – implement e-expenses and ADI upload	RB	PM			E-expenses Oct ADI upload Decr	
<ul> <li>IT: Maintain the availability of key IT services (% availability)</li> </ul>	AMcD	BAU	≥99.95%	≥99.95%	≥99.95%	≥99.95%
<ul> <li>IT: Maintain customer satisfaction with services offered at the desktop</li> </ul>	AMcD	BAU	≥70%	≥70%	≥70%	≥70%
<ul> <li>Finance: Better Payment Practice Code by volume and value</li> </ul>	RB	BAU	≥92.00%	≥92.00%	≥92.00%	≥92.00%
<ul> <li>Finance: Number of debtor days</li> </ul>	RB	BAU	20	20	20	20

Strategic Activity EA 2 Build support for the NHSBT strategy through a programme of proactive engagement with internal and external stakeholders.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4	
• HR: continued development of more effective consultative structures and an effective policy framework, developed in partnership	DE	BAU	Ongoing	Ongoing	First Phase Revisions in place		
<ul> <li>HR: develop and implement a revised action plan in response to the 2008 staff survey and improve the response rate to the 2009 survey to over 45%.</li> </ul>	DE	BAU	Action Plan agreed			Response rate improved to 45%	
• HR: develop and implement a Single Equality Scheme and associated Action Plan	DE	BAU	SES agreed and adopted				
<ul> <li>Communications &amp; PA: Build on progress made in strategic stakeholder engagement on NBS review and launch of ODTF reports of that this becomes part of business as usual across NHSBT</li> </ul>	HJ	BAU	Engagement Plans developed				
• Finance: Ensure that sufficient funding is generated, effectively managed and made available in line with planned requirements	RB	BAU					
Support to the NCG for Blood process				NCG1 July	NCG 2 November		
Submission of revenue, brokerage and capital GIA bids in line with the DH planning timetable.					Mid December		
<ul> <li>Finance: Continued delivery of a supplier development programme</li> </ul>	RB	BAU	7 key suppliers	8 key suppliers	9 key suppliers	10 key suppliers	
<ul> <li>DSM: Establish process for self-regulation in line with DH gateway arrangements</li> </ul>	ТМ	BAU		Agreed by Mid-year		Implement	
o DSM: Effective development and deployment of an NHSBT planning framework, working within DH guidelines and frameworks	тм	BAU	Review and agree process, update strategic direction by end of Q1	Outline plans 2009/12 to Nov Board Planning day and draft documents to the DH	Refine plans to reflect DH feedback and in-year performance	Board and DH approval by March	
<ul> <li>Clinical: Engage stakeholders on the implementation, success monitoring and roll out of BBTIII and relevant and influential clinica audit outcomes and systematic reviews.</li> </ul>	l LW	BAU	Workplan for Clinical Audit	Greater involvement through NBTC Executive sub-group	Take part in public awareness day	Ongoing	

Strategic Activity EA 2 Build support for the NHSBT strategy through a programme of proactive engagement with internal and external stakeholders.	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
<ul> <li>Clinical: Engage with clinical colleagues in NHS Hospital Trusts involved in transplantation, to help ensure the successful implementation of the Organ Donation Taskforce recommendations.</li> </ul>	LW	BAU	Develop job descriptions for clinicians to lead	Appoint to clinical lead posts within NHSBT	Activities as part of ODO plans	Activities as part of ODO plans
<ul> <li>E&amp;L: Develop an outline Estates and Logistics Strategic Plan in line with 'internal' stakeholder requirements</li> </ul>	DD	BAU				By March
Survey estates utilisation, suitability, cost and condition against internal stakeholders' needs	DD	BAU		Commence survey	Complete survey and report	
Develop and implement 5 year estates investment plans to meet internal stakeholders' needs	DD	BAU				Propose draft Plans
Review warehouse operations models against internal stakeholders' needs and propose improvements	DD	BAU		Complete review		

	gic Activity EA3 Improve NHSBT's capacity and capability to deliver strategic change through the deployment of briate resource, leadership and skill, supported by the development of appropriate performance management systems	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
0	<ul> <li>HR: Provide effective support to key strategic organisational changes, in particular;</li> <li>Completion of the Filton and South West project</li> <li>Implementation of the Organ Donation Taskforce recommendations</li> <li>Transformational change within Donor Services</li> </ul>	DE	BAU	Ongoing	Ongoing	Ongoing	Ongoing
0	HR: Introduce a new system of HR KPIs which will allow more effective workforce management by line managers	DE	BAU	Ongoing	KPIs Introduced		
0	<ul> <li>HR: In conjunction with the relevant Directors, ensure a significant reduction by year-end in absence levels in areas with high absence rates. Key target areas - Donor Services and Estates/Logistics, as follows:</li> <li>E&amp;L – 2% reduction by year end</li> <li>Donor Services – 1.25% reduction by year end</li> </ul>	DE	BAU	Revised absence policy implemented	New monitoring system in place	Targeted action	Target reductions achieved in key areas
0	HR: Develop and implement a new Appraisal and Personal Development Review Process, linked to E-KSF.	DE	BAU			Consultation on new system	New system launched
0	HR: Implement improved control and monitoring systems for the management of Agency/temporary staffing.	DE	BAU	Controls in place			
0	HR: To ensure that an effective Leadership and Management Development programme is designed and implemented in support of strategic priorities	DE	BAU	Priorities identified	Programme spec developed	Resource identified /tender process completed	Revised programme in place
0	IT: Continue to ensure that effective programme management structures are available to support business change in all operating divisions, including the provision of appropriate resources, standards and governance frameworks	AMcD	BAU	Roll-out of new lifecycle & associated templates continues	Roll-out of new lifecycle & associated templates complete		
0	IT: Continue to ensure that suitable and sufficient Project Management resources are available to deliver NHSBT initiatives, and that appropriate project management standards and methods are developed and deployed	AMcD	BAU		Extend / replace the contract to provide project managt support to the change programme.	Ensure project managt support is commensur ate with NHSBT strategic needs	Ensure project managt support is commensur ate with NHSBT strategic needs

	ic Activity EA3 Improve NHSBT's capacity and capability to deliver strategic change through the deployment of riate resource, leadership and skill, supported by the development of appropriate performance management systems	Resp Dir.	PM / BAU	Quarter 1	Quarter 2	Quarter 3	Quarter 4
0	DSM: Development of improved performance management systems, frameworks and processes	ТМ	РМ		Recommend ations and actions agreed	Begin to implement	
0	Clinical: Review Clinical Directorate workforce requirements and geographical spread in light of NBS strategy review – appoint to new joint posts in Transfusion Medicine (with HPA), Tissue Services (Wrightington Hospital), and in Nottingham, Liverpool, Kings, and St. Mary's London. Review arrangements in Birmingham and Manchester. Implement new contract for non-consultant career grade doctors in line with national arrangements and develop.	LW	BAU	Finalise JDs, and advertise tissues, epidemiolog y, Kings, Nottingham	Finalise JDs and advertise St. Mary's	Review arrangement s in Birmingham and Manchester	Plan for Liverpool
0	Clinical: Provide support for the replacement of the Chair of UK JPAC, and assist with the review of JPAC modus operandi	LW	BAU	Develop JD for Chair of JPAC	Appoint Chair of JPAC	Review JPAC modus operandi	Implement changes

## **NHS** Blood and Transplant

## PLAN 2008/09 CONSOLIDATED REVENUE STATEMENT

Plan 07/08	Forecast	Plan 08/09
£k	07/08 £k	£k
33 732	29 842	27,354
· ·		7,702
-	-	23,000
,	,	447,537
· ·		1,863
		507,456
	· · · · · · · · · · · · · · · · · · ·	(15,700)
		· · · · ·
463,001	450,939	491,756
247,707	245,207	257,341
		97,024
9,422	9,422	15,439
348,619	343,117	369,804
		0.57
		957
	,	3,543
	,	55,919
	,	7,103 7,432
· ·	,	18,963
		10,831
	,	927
		8,978
		23,000
	,	137,652
		(15,700)
114,382	104,822	121,952
0	3 000	0
	3,000	<u> </u>
	33,732 0 20,000 427,456 1,813 <b>483,001</b> (20,000) <b>463,001</b>	£k         07/08 £k           33,732         29,842           0         0           20,000         20,000           427,456         422,284           1,813         1,813           483,001         473,939           (20,000)         (23,000)           463,001         450,939           247,707         245,207           91,490         88,488           9,422         9,422           348,619         343,117           933         933           3,713         3,713           3,713         3,713           54,506         54,479           7,042         7,026           7,305         7,442           18,719         18,719           9,792         9,792           854         854           11,518         1,864           20,000         23,000           134,382         127,822           (20,000)         (23,000)           114,382         104,822

# **NHS** Blood and Transplant

## PLAN 2008/09 CONSOLIDATED BALANCE SHEET

	Forecast 07/08 £k	Plan 08/09 £k
Fixed Assets	346,945	368,002
<u>Current Assets</u> Stocks Trade Debtors Prepayments Other Debtors Bank and Cash Less:-	57,965 20,590 6,219 2,993 70 87,837	58,384 20,119 5,600 4,166 70 88,339
<u>Current Liabilities</u> Trade Creditors Accruals Inter Authority Loan Others	15,411 12,401 0 <u>2,689</u> 30,501	13,411 13,680 0 <u>4,925</u> 32,016
Net Current Assets	57,336	56,323
Provisions Total Net Assets	3,088 401,193	3,088 421,237
Represented by:-		
<u>Department of Health Funding</u> General Reserve Revaluation Reserve	401,193	421,237
Total Dept of Health Funding	401,193	421,237

Appendix 2 (c)

### CONSOLIDATED CASH FLOW FORECAST PLAN 2008/09

**NHS** Blood and Transplant

	Apr-08	May-08	Jun-08	Jul-08	Aug-08	Sep-08	Oct-08	Nov-08	Dec-08	Jan-09	Feb-09	Mar-09	Total
	£k	£k											
Opening bank balance	70	8,578	11,131	13,686	16,240	18,793	21,347	20,810	20,272	19,736	18,821	17,528	70
Income													
Debtors & Other Receipts	37,450	37,450	37,450	37,450	37,450	37,450	37,450	37,450	37,449	37,450	37,450	37,451	449,400
Revenue Cash Limit	10,295	4,341	4,341	4,340	4,340	4,341	4,341	4,341	4,342	4,341	4,341	4,352	58,056
Inter year flexibility out												-15,700	-15,700
Capital Cash Limit	2,277	2,281	2,281	2,281	2,281	2,281	2,280	2,280	2,281	2,280	2,281	2,281	27,365
Total income	50,022	44,072	44,072	44,071	44,071	44,072	44,071	44,071	44,072	44,071	44,072	28,384	519,121
Expenditure													
Staff Expenses	16,871	16,871	16,871	16,871	16,871	16,871	16,974	16,974	16,973	17,168	17,365	17,374	204,054
Other Revenue costs	19,277	19,277	19,277	19,277	19,277	19,277	22,265	22,265	22,265	22,448	22,631	22,967	250,503
Capital Charges	3,089	3,090	3,088	3,089	3,089	3,089	3,089	3,089	3,089	3,090	3,088	3,220	37,199
Capital costs	2,277	2,281	2,281	2,280	2,281	2,281	2,280	2,281	2,281	2,280	2,281	2,281	27,365
Total costs	41,514	41,519	41,517	41,517	41,518	41,518	44,608	44,609	44,608	44,986	45,365	45,842	519,121
Closing bank balance	8,578	11,131	13,686	16,240	18,793	21,347	20,810	20,272	19,736	18,821	17,528	70	70

## **NHS** Blood and Transplant

## PLAN 2008/09 CONSOLIDATED FUNDS FLOW STATEMENT

	Forecast 07/08 £k	Plan 08/09 £k
Surplus/(Deficit)	0	0
(Increase)/Decrease in stocks (Increase)/Decrease in trade debtors (Increase)/Decrease in prepayments and other debtors Increase/(Decrease) in trade creditors & accruals Increase/(Decrease) in other creditors Increase/(Decrease) in other creditors Increase/(Decrease) in Inter Auth Loan Increase/(Decrease) in provisions	(57,965) (20,590) (9,212) 27,812 2,689 0 <u>3,088</u> (54,178)	(419) 471 (554) (721) 2,236 0 <u>0</u> 1,013
Increase/(Decrease) in working capital	(54,178)	1,013
Opening cashbook balance Closing cashbook balance	114 70	70 70
Increase/(Decrease) in cash	(44)	0

# **NHS** Blood and Transplant

## PLAN 2008/09 CAPITAL EXPENDITURE PLAN

	2008/09 £m
South West Regional Restructuring - Bristol Filton New Build	7.815
South West Regional Restructuring - minor equipment	4.207
Specialist services system replacement	0.191
Minor Capital Programme	8.652
BPL Capital Programme	6.500
Total NHSBT	27.365

Objective (a)	Blood Components												
	What do we want to do?	How will we know? What will be different in 2008/09/10/11?	What will stop us?	How is the risk controlled	How do we know the risk is controlled?	What are the gaps in managing the risk	What should we do about the risk gaps		Following quarterly review, has the risk moved up, down or stayed the same?				
Blood Supply Chain (BSC)	Principal corporate objective	Success criteria / end outcome and expected dates	Constraints / risks to meeting the objective	Control	Assurance	Gaps identified	Priorities for actions from risk, control, assurance, gaps	Risk rating	Movement in risk rating	Lead			
	To provide a sustainable supply of blood component products and services that meet all safety, quality, service provision and compliance standards, as efficiently as possible, via the modernisation of the blood component supply chain.	BSC1a Blood collection target achieved (100% -2007/08 / 100% -2008/09 and onwards) BSC 1b / 1c Blood donor satisfaction levels increase ( 63% - 07/08 / 65% - 08/09 / 68% - 09/10 / 73% - 10/11)	<b>BSC1</b> Turnover in donors - active donor database declining at a faster rate than the decline in demand. <b>BSC1</b> Blood collection model not providing the right environment for donors - blood stocks are falling below optimum levels.	<b>BSC1</b> Ensure the collection of sufficient red cells and platelets to meet current and future demand by modernising blood collection activities.	BSC – Overall progress overseen by NHSBT Board and Executive Management Team. (Minutes of Meetings)	progress overseen by NHSBT Board and Executive Management Team. (Minutes of	progress overseen by NHSBT Board and Executive Management Team. (Minutes of	progress overseen by NHSBT Board and Executive Management Team. (Minutes of	None	None			CRo
		<b>BSC 2</b> Cost reduction target - £10.5m - 07/08, £10.2m - 08/09, £11.1m - 09/10, £15.4m - 10/11	<b>BSC 2</b> Stakeholder pressure to reduce costs and stabilise previously rising prices. <b>BSC 2</b> NHSBT behind European counterparts on efficiency and productivity benchmarks.	<b>BSC2</b> Avoid further significant increases in red cell prices by reducing costs and improving efficiency in line with expected falls in blood demand.	Quarterly and Monthly Performance Reports					CRo			
		<b>BSC 3a</b> Productivity within Processing and Testing no of red cell (equivalent) units per WTE - 5,200/WTE 07/08, 5,300/WTE 08/09, 6,300 WTE 09/10 & 7,000/WTE 10/11. <b>BSC 3b</b> Reduction in external non- compliances with overdue actions – 14% - 07/08, 0% - 08/09 - 10/11 <b>BSC 3c</b> % of Hospitals satisfied with overall service (Top Box) 50% - 07/08, 53% - 08/09, 56% - 09/10, 60% - 10/11.	<ul> <li>BSC 3a Significant over capacity exists and will grow if not addressed.</li> <li>BSC 3b/c Product and service infrastructure will not meet future regulatory and safety requirements without corrective action.</li> </ul>	<b>BSC3</b> Ensure that the organisation has the appropriate level of capacity and capability to process blood to the standards required by modernising its production and testing infrastructure.	At a Divisional Level, overseen by NBS SMT. Also:- Donor Services SMT Minutes Process, Testing and Issues SMT		ices es						CRo
		<b>BSC 4</b> Year-on-year reduction in red cell issues 1.820m in 07/08 1.765m (-3.0%) in 08/09 1.724m (-2.3%) in 09/10 1.700m (-1.4) in 10/11	<b>BSC 4</b> Some blood component products continue to cause adverse reactions in patients.	<b>BSC4</b> Reduce the residual risk of transfusion through continued implementation of agreed blood safety initiatives.	minutes					CRo/ LW			

Objective (b)	Specialist Services									
	What do we want to do?	How will we know? What will be different in 2008/09/10/11?	What will stop us?	How is the risk controlled	How do we know the risk is controlled?	What are the gaps in managing the risk	What should we do about the risk gaps		Following quarterly review, has the risk moved up, down or stayed the same?	
Specialist Services (SS)	Principal corporate objective	Success criteria / end outcome and expected dates	Constraints / risks to meeting the objective	Control	Assurance	Gaps identified	Priorities for actions from risk, control, assurance, gaps	Risk rating	Movement in risk rating	Lead
Servic financ while quality provis	To move Specialist Services towards financial sustainability, while maintaining quality, service provision and	Contribution to reduced funding gap: <b>SS1 (Pricing)</b> £5.4m -08/09, £1.4m - 09/10, £1.4m - 10/11	<b>SS1, 2 &amp; 3</b> Ability to meet growing demand for many NHSBT specialist services.	<b>SS1</b> Implement appropriate funding and pricing strategies to eliminate inappropriate cross-subsidies.	s progress overseen by NHSBT Board and Executive Management Team. (Minutes of Meetings)	None	None			PAG
	compliance standards.	Contribution to reduced funding gap: <b>SS2 (Growth)</b> £0.0m - 08/09, £0.8m - 09/10, £0.7m - 10/11	fit with wider NHSBT supply chain.	SS2 Expand in areas of anticipated high growth without increasing capacity unnecessarily.						
		Contribution to reduced funding gap: <b>SS3 (Cost reduction)</b> £0.7m - 08/09, £2.0m - 09/10, £1.0m - 10/11	SS1, 2 & 3 Services are currently subsidised by income from the provision of blood component products.	<b>SS3</b> Reduce costs and improve efficiency from realising synergies, consolidation and divesting from activities in a managed way ensuring continued patient safety.	Performance Reports At a Divisional Level, overseen by NBS SMT.					
		SS4 Maintenance of Quality a) Reduction in external non- compliances with overdue actions - 7% - 07/08, 0% - 08/09 to 10/11. b) SLA Compliance 95% 07/08 to 10/11 c) Tissues: orders met on time in full (OTIF) 96% - 07/08, 98.5% - 08/09 to 10/11	<b>SS4</b> Failure in quality levels could lead to harm / death to patients and loss of license / accreditation	<b>SS4</b> Ensure that service quality levels are maintained or improved during the ongoing change programme.	Also:- Specialist Services SMT Minutes					

Objective (c)	Organ Donation									
·	What do we want to do?	How will we know? What will be different in 2008/09/10/11?	What will stop us?	How is the risk controlled	How do we know the risk is controlled?	What are the gaps in managing the risk	What should we do about the risk gaps		Following quarterly review, has the risk moved up, down or stayed the same?	
Organ Donation (OD)	Principal corporate objective	Success criteria / end outcome and expected dates	Constraints / risks to meeting the objective	Control	Assurance	Gaps identified	Priorities for actions from risk, control, assurance, gaps	Risk rating	Movement in risk rating	Lead
	To identify and refer increasing numbers of potential donors and to increase the number of actual donors, enabling an increase in the number of transplants.	<b>OD1</b> % of patients where BSD is a possible diagnosis that following identification, testing and referral are suitable donors - 70% - 07/08, 76% - 08/09, 78% - 09/10, 80% -10/11.	<ul> <li><b>OD1</b> Current structures and arrangements act as a barrier to organ donation. Organs are currently retrieved from 30%-40% of potential donors.</li> <li><b>OD1</b> Organ donation is not effectively performance managed within the NHS.</li> </ul>	<b>OD1</b> Remove the obstacles to organ donation and effectively performance manage the identification and referral of potential donors.	OD – Overall progress overseen by NHSBT Board and Executive Management Team. (Minutes of Meetings)	None	None			TM/ CRu
		<b>OD2</b> % of HB donor families approached that consent to / authorise donation within ICU - 61% - 07/08, 63% - 08/09, 66% - 09/10, 69% - 10/11.	<b>OD2</b> Current donor co-ordination arrangements are fragmented and are not sustainable for the future.	<b>OD2</b> Maximise the conversion of potential donors into actual donors by developing and implementing a robust, sustainable donor co- ordination service.	Quarterly and Monthly Performance Reports At a Divisional Level, overseen by UKT SMT. Also Performance Reporting to DH around implementation of Organ Donation Taskforce Findings	onthly erformance				
		OD3 Number of transplants per donor -           HB - 3.91 - 07/08, 3.91 - 08/09, 3.95 -           09/10, 3.95 - 10/11           N-HB - 2.35 - 07/08, 2.35 - 08/09, 2.40 -           09/10, 2.45 - 10/11	<b>OD3</b> Current organ retrieval arrangements are fragmented and are not sustainable for the future.	<b>OD3</b> Develop and implement a flexible, robust and sustainable organ retrieval service that delivers viable organs to transplant units.						
		<b>OD4</b> % no. of corneas that is sufficient to meet demand - 84% - 07/08, 91% - 08/09, 100% - 09/10 & 10/11.	<b>OD 4</b> Current eye retrieval arrangements are fragmented and are not sustainable for the future.	<b>OD4</b> Develop and implement a robust, sustainable cornea donation service.						
		<b>OD5</b> People on ODR 15.0m - 07/08, 15.7m - 08/09, 16.3m – 09/10, 16.9m - 10/11	<b>OD5</b> There is an urgent need to address health inequalities particularly for people of Asian or Afro-Caribbean origin.	<b>OD5</b> implement methods to publicly recognise the act of donation and actively promote donation to the public.						

Objective (d)	Fractionated Products											
	What do we want to do?	How will we know? What will be different in 2008/09/10/11?	What will stop us?	How is the risk controlled	How do we know the risk is controlled?	What are the gaps in managing the risk	What should we do about the risk gaps		Following quarterly review, has the risk moved up, down or stayed the same?			
Fractionated Products (FP)	Principal corporate objective	Success criteria / end outcome and expected dates	Constraints / risks to meeting the objective	Control	Assurance	Gaps identified	Priorities for actions from risk, control, assurance, gaps	Risk rating	Movement in risk rating	Lead		
	To achieve financial viability while continuing to meet all quality, service provision and	<b>FP1</b> Cumulative % increase in annual fractionation capacity - 4% - 08/09, 9% - 09/10, 16% - 10/11.		FP1 Increase capacity and throughput. FP – Overall progress overseen by NHSBT Board and Executive	progress overseen by NHSBT Board and Executive Management	None	None			ML		
	compliance standards.	<ul> <li>FP2.1 Launch new products: Full scale optivate sales UK/Brazil – 07/08 Optivate &amp; Replenine sales in Europe – 08/09 Gammaplex sales factor X named patient – 09/10 Optivate VWD sales, Factor X sales – 10/11</li> <li>FP2.2 Contract fractionation and licensing out IP Kazpharm (LO) – 07/08 Gammacan (CFr) Recombinant Anti-D (LO) – 08/09 Secure small scale contract fractionation – 09/10 Secure large scale contract fractionation – 10/11.</li> </ul>		FP2 Develop new products and expand into key markets.	Management Team. (Minutes of Meetings) Quarterly and Monthly Performance Reports At a Divisional Level, overseen by BPL SMT.							
		FP3 Cumulative % increase in sales revenues - 13% - 08/09, 26% - 09/10, 37% - 10/11.		<b>FP3</b> Increase home and export sales revenues.								
		<b>FP4</b> Consider Options for Commercial Partnership - OBC complete - 07/08, Plan response to OBC review - 08/09	<b>FP4</b> BPL is a relatively small player in a competitive global market, which impacts on plasma supply, product supply and prices.	<b>FP4</b> Consider options for commercial partnership.								

Objective (e)	NHSBT: An organis	ation fit for purpose											
	What do we want to do?	How will we know? What will be different in 2008/09/10/11?	What will stop us?	How is the risk controlled	How do we know the risk is controlled?	What are the gaps in managing the risk	What should we do about the risk gaps		Following quarterly review, has the risk moved up, down or stayed the same?				
NHSBT: An organisation fit for purpose	Principal corporate objective	Success criteria / end outcome and expected dates	Constraints / risks to meeting the objective	Control	Assurance	Gaps identified	Priorities for actions from risk, control, assurance, gaps	Risk rating	Movement in risk rating	Lead			
	To establish NHSBT as an acknowledged, effective and efficient provider of products and services, focused on service to donors and customers, flexible to meet changing needs and ambitious to succeed.	Achievement of BSC, SS, OD and FP Objectives Further success criteria to be developed	<b>EA1</b> Current organisational structures and systems are not conducive to successful delivery of changes to front line services Some Group Service costs are in excess of external benchmarks.	ructures and systems are not onducive to successful delivery changes to front line services ome Group Service costs are in ccess of external benchmarks.	progress overseen by NHSBT Board and Executive Management Team. (Minutes of	progress overseen by NHSBT Board and Executive Management Team. (Minutes of Meetings) Quarterly and	progress overseen by NHSBT Board and Executive Management Team. (Minutes of Meetings)	progress overseen by NHSBT Board and Executive Management Team. (Minutes of Meetings)	able effective and ery of its strategy rovision of d systems.	All Group Service functions are developing detailed resource plans with success criteria to support delivery of			LH
			<b>EA2</b> Difficult to secure support for strategic plans from multiple stakeholders with conflicting interests.	<b>EA2</b> Build support for the NHSBT strategy through a programme of proactive engagement with internal and external stakeholders.		the ab	the above objectives						
	EA3 Insufficient leadership skill skilled resource and workforce capability in some areas to deliv a challenging change agenda. Lack of a performance led cultur within NHSBT.	<b>EA3</b> Improve NHSBT's capacity and capability to deliver strategic change through the deployment of appropriate resource, leadership and skill, supported by the development of appropriate performance management systems.	At a Divisional & Group Services Level, overseen by NBS, BPL, UKT, Finance, HR E&L, IT, Clinical, PCA and SD SMTs.										

## **APPENDIX 4 - Emergency Preparedness**

### The NHSBT Emergency Planning System

NHSBT is a key health provider within the NHS. Without blood, transplantation, tissues and other services the NHS would rapidly find its capabilities significantly compromised. NHSBT services must not falter or fail. NHSBT therefore takes its responsibility for emergency preparedness (including business continuity) extremely seriously. NHSBT has a comprehensive and mature Emergency Planning System that has been developed to meet the needs of NHSBT within the wider healthcare system.

Central to the Emergency Planning System are cohesive and integrated crisis management arrangements based on a single, robust, national to local command and control structure. In addition to this over-arching system, there are detailed major incident supporting plans and continuity plans for each Operating Division / Function. Many key Group Services functions have detailed emergency plans that aim to support the wider organisation's emergency arrangements.

### Governance

The NHSBT Chief Executive takes personal responsibility for Emergency Planning, exercising these responsibilities on behalf of the NHSBT Board, using an Emergency Planning Group structure which reflects the organisation as a whole. The NHSBT Board receives a report on Emergency Planning arrangements at least annually.

### Standards

The following current legislation, guidance and standards are relevant to developing and maintaining Emergency Planning across NHSBT;

- Civil Contingencies Act (CCA) 2004 and its associated Guidance,
- Healthcare Commission Core Standard C24 Major Incident Planning,
- NHS Emergency Planning Guidance 2005,
- UK Pandemic Influenza Planning Guidance 2007,
- Business Continuity Standard BS25999:1&2 2006/2007.

Although NHSBT does not currently have statutory obligations under the CCA, it is important as a public service provider that it continuously works toward ensuring that it's Emergency Planning System is aligned and consistent with all of the above regulations, standards and guidance.

#### Activities Within 2007/08

The main focus for the year was Pandemic Flu. Although scientific and medical understanding of the impact of Pandemic Flu is still evolving, NHSBT has made progress in the development and publication of its plans, both in terms of internal resilience and its response to wider healthcare pressures. By the end of 2007/08 business year, NHSBT will have completed its second full Pandemic Flu planning cycle updating its plans in light of the latest (2007) UK Government guidance.

Detailed areas of development for Pandemic Flu in 2007/08 have included;

- Infection control guidance,
- Staffing,
- Donor and Patient facing plans,
- Impact on Operations,

## **APPENDIX 4 - Emergency Preparedness**

- Blood shortage plans,
- Supply chain assessment, including critical suppliers,
- Communication planning,
- IT and remote working.

NHSBT played an active part in 'Exercise Winter Willow', co-ordinating the UK Blood response and contributing to national feedback, as well as responding formally to the consultation on new draft UK Government plans. As a result, NHSBT services now have a profile in central UK plans which would otherwise not be the case. NHSBT also participated in 'Exercise Phoenix'. Areas for further Pandemic Flu plan development include completing the above items and developing an adjusted Command and Control system for deployment in the event of a prolonged Pandemic Flu outbreak.

In addition to Pandemic Flu, other Emergency Planning activities have included: keeping the system up to date, training, running necessary practices, monitoring the system and identifying learning points. In addition, relationships with other UK Blood Services and international collaborations to assist NHSBT's preparedness have been developed in 2007/08.

Planning against new Government fuel shortage guidance is also being undertaken and the NBS antidote service provision is being reviewed.

### Activities Planned for 2008/11

Early 2008 will see the appointment, induction and development of the new Head of Emergency Planning as well as the continued use of expert external support services in this key area. There will therefore be an opportunity to review more fully the arrangements and strategic direction for NHSBT's Emergency Preparedness in 2008/09. This will, of course, be done without compromising existing arrangements.

Further development work will be required for Pandemic Flu (see above) and NHSBT will need to formally confirm its state of preparedness for this eventuality as will all other NHS organisations. Preparedness will be gauged against a planned NHS audit tool being developed by the Department of Health (DH). In addition, in 2008/09 we will bring forward proposals for stock-piling of flu specific consumables in 2009/10 (where relevant). The stated goal is for "all NHS organisations to have robust plans in place" (Secretary of State to House of Commons, Nov 22 2007). Planners at the DH are setting a deadline of end 2008 for the NHS to be "ready to implement", although stock-piling is expected to take until 2010 to complete.

Specific planned activities for 2008/09 also include;

- Completion of 2008 UK Capabilities Survey,
- Develop and deliver new training cycle for National Emergency Planning Managers,
- Closer integration of NHSBT EP system with Department of Health at EPD level,
- Improve pandemic preparedness through further training and exercising,
- Self assessment (HC Standard 24 plus possible external HC assessment),
- NHS self audit on Pandemic Flu planning (plus possible NHS audit of NHSBT),
- Addressing gaps, actions and learning arising from above processes,
- Implement renewed SLA with DH on Antidote Service provision,
- Fulfil all obligations for practising, training and monitoring and learn from activations,
- Commence review of EP system against BS25999 (Business Continuity).

## **APPENDIX 5 - Sustainable Development Action Plan**

### Introduction

The document "Securing the Future – UK Government Sustainable Development Strategy" was issued in 2005 and updated the Governments previous strategy of 1999, which set out to help deliver a better quality of life through sustainable development. It outlines a number of requirements, targets and aspirations on sustainability, towards which all Government departments and executive agencies must work.

This paper is a high-level summary of the actions planned by NHSBT to meet and fulfil its obligations on Sustainable Development.

### Background

Sustainable development is based on five key principles;

- Living within environmental limits,
- Ensuring a strong healthy and just society,
- Achieving a sustainable economy,
- Promoting good governance, and
- Using sound science responsibly.

Within these principles, there are currently four priority areas which agencies are being asked to address;

- Sustainable consumption and production,
- Climate change and energy,
- Natural resource protection and environmental enhancement, and
- Sustainable communities.

Although there is no current mandate for ALB's to meet new Government targets on sustainability, there are strong indications that these targets will be compulsory in the very near future.

#### NHSBT 2008/11 Plan

During 2008/09 NHSBT will develop a Sustainable Development Action Plan (SDAP) as part of the first steps to embedding sustainable development activities into the organisation over the 2008/11 period. This will include:

- Development of adequate structures and processes to manage the formulation, execution and performance management of the plan,
- Establishment of formal links with the DH lead on sustainable development and the Sustainable Development Commission,
- Implementation of appropriate communications and robust governance arrangements,
- Establishment of a baseline position against published targets for Sustainable Operations on the Government Estate (SOGE),
- Production of a Sustainable Procurement Strategy, and
- Integration of SDAP planning into the extant planning process and associated procedures.

- ABO | Major Blood Grouping system (Types A, B, AB, O)
- ALBR Arms Length Body Review
- ABC/M Activity Based Costing / Management
- *BBMR* British Bone Marrow Registry
- *BBT III* Better Blood Transfusion 3 (A DH initiative led by the CMO)
  - BME Black and Minority Ethnic
  - BPL Bio-Products Laboratory
  - BSE Bovine spongiform encephalopathy
  - CBB Cord Blood Bank
  - *CMO* Chief Medical Officer
  - DH Department of Health
- *ESOR* Economics Statistics & Operational Research (department within DH)
- ESR Electronic Staff record (National database initiative within NHS)
- FFP Fresh Frozen Plasma
- GIA Grant in Aid (Central cash-limit funding from the Department of Health)

Granulocytes contain enzymes that digest micro-organisms

The science of antibodies directed against antigens on the surface of white blood cells.

Granulocyte Immunology

### H&I

HB Heart-Beating (relating to organ donation)

Haematology and Immunogenetics

- IBGRL International Blood Group Reference Laboratory
  - ICUs Intensive Care Units
    - *KSF* Key Skills Framework
- LIMS Laboratory Information Management System
- NBS National Blood Service
- NBTS National Blood Transfusion Committee
- *NCG* National Commissioning Group (Through which price of blood is agreed annually)
- NHSBTNational Health Service Blood and Transplant, the new authority formed on October 1st,<br/>2005, through the merging of NBA and UKTNHSLANHS Litigation Authority
- INTIS LINGATION AUTIONLY
- NPSA National Patient Safety Agency
- OBC review Outline Business Case review
  - ODO Organ Donation Organisation
  - ODTF Organ Donation Task Force
    - PAS | Platelet Additive Solution
    - PDR | Personal Development Review
    - PGI Platelet & Granulocyte Immunology

PlasmaThe extraction of a variety (over 700) of proteins from Human plasma which are of<br/>considerable therapeutic value

### Glossary of Terms

Prion Abnormal prions (small proteinaceous infectious particles) can attack the brain, killing cells and creating gaps in tissue or sponge-like patches. The vCJD prion is the same prion found in cows with Bovine Spongiform Encephalopathy (BSE). Research companies are looking to develop abnormal prion reduction systems, (primarily filters) to remove prions from donated blood.
 PTI Processing Testing and Issue

- *R&D* | Research and Development
- RCI Red Cell Immunohaematology
- *SaBTO* Advisory Committee on the safety of Blood, Tissues and Organs
  - SAS Industry standard Business / Finance software
  - SBS | Shared Business Services
  - SCI Stem Cell Immunotherapy
- *SDAP* Sustainable Development Action Plan
- *SHOT* | Serious Hazards of Transfusion
- SLA | Service Level Agreement
- TRALI | Transfusion Related Acute Lung Injury
  - UKT UK Transplant
- VCJD Variant Creutzfeldt-Jakob Disease
- WTE Whole Time Equivalent